P1089: BRENTUXIMAB VEDOTIN, NIVOLUMAB, DOXORUBICIN, AND DACARBAZINE (AN+AD) FOR ADVANCED STAGE CLASSIC HODGKIN LYMPHOMA: PRELIMINARY SAFETY AND EFFICACY RESULTS FROM THE PHASE 2 STUDY (SGN35 027 PART B). (23rd June 2022)

Record Type:: Journal Article
Title:: P1089: BRENTUXIMAB VEDOTIN, NIVOLUMAB, DOXORUBICIN, AND DACARBAZINE (AN+AD) FOR ADVANCED STAGE CLASSIC HODGKIN LYMPHOMA: PRELIMINARY SAFETY AND EFFICACY RESULTS FROM THE PHASE 2 STUDY (SGN35 027 PART B). (23rd June 2022)
Main Title:: P1089: BRENTUXIMAB VEDOTIN, NIVOLUMAB, DOXORUBICIN, AND DACARBAZINE (AN+AD) FOR ADVANCED STAGE CLASSIC HODGKIN LYMPHOMA: PRELIMINARY SAFETY AND EFFICACY RESULTS FROM THE PHASE 2 STUDY (SGN35 027 PART B)
Authors:: Lee, H.
Flinn, I. W.
Melear, J.
Ramchandren, R.
Friedman, J.
Burke, J. M.
Linhares, Y.
Raval, M.
Chintapatla, R.
Feldman, T. A.
Yimer, H.
Islas-Ohlmayer, M.
Dean, A.
Rana, V.
Gandhi, M. D.
Renshaw, J.
Gillespie-Twardy, A. L.
Ho, L.
Puhlmann, M.
Guo, W.
Yasenchak, C. A.
Abstract:
Is Part Of:: HemaSphere. Volume 6(2022)Supplement 3
Journal:: HemaSphere
Issue:: Volume 6(2022)Supplement 3
Issue Display:: Volume 6, Issue 3 (2022)
Year:: 2022
Volume:: 6
Issue:: 3
Issue Sort Value:: 2022-0006-0003-0000
Page Start:: 979
Page End:: 980
Publication Date:: 2022-06-23
Subjects:: Hematology -- Periodicals
616.15005
Journal URLs:: https://journals.lww.com/hemasphere/pages/default.aspx ↗
http://journals.lww.com/pages/default.aspx ↗
DOI:: 10.1097/01.HS9.0000847224.76139.00 ↗
Languages:: English
ISSNs:: 2572-9241
Deposit Type:: Legaldeposit
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:: British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store
Ingest File:: 22734.xml